Jeremie Calais

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6625346/publications.pdf

Version: 2024-02-01

118 papers	4,930 citations	101543 36 h-index	102487 66 g-index
121 all docs	121 docs citations	121 times ranked	3621 citing authors

#	Article	IF	Citations
1	Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. JAMA Oncology, 2019, 5, 856.	7.1	493
2	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. Journal of Nuclear Medicine, 2018, 59, 469-478.	5.0	372
3	18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncology, The, 2019, 20, 1286-1294.	10.7	338
4	⁶⁸Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. Journal of Nuclear Medicine, 2018, 59, 230-237.	5.0	226
5	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 7448-7454.	7.0	190
6	Metaanalysis of ⁶⁸Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. Journal of Nuclear Medicine, 2019, 60, 786-793.	5.0	169
7	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 67S-76S.	5.0	163
8	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). European Urology, 2021, 80, 280-292.	1.9	140
9	Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. JAMA Oncology, 2021, 7, 1635.	7.1	138
10	Radiation Dosimetry and Biodistribution of ⁶⁸Ga-FAPI-46 PET Imaging in Cancer Patients. Journal of Nuclear Medicine, 2020, 61, 1171-1177.	5.0	136
11	Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncology, The, 2021, 22, 1115-1125.	10.7	120
12	Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4377-4385.	6.4	114
13	Impact of ⁶⁸Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. Journal of Nuclear Medicine, 2018, 59, 434-441.	5.0	113
14	⁶⁸Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. Journal of Nuclear Medicine, 2017, 58, 1617-1623.	5.0	111
15	Impact of ⁶⁸Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. Journal of Nuclear Medicine, 2020, 61, 1153-1160.	5.0	94
16	Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer, 2019, 19, 18.	2.6	86
17	Potential Impact of ⁶⁸Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1714-1721.	5.0	81
18	Impact of ⁶⁸Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. Journal of Nuclear Medicine, 2020, 61, 1793-1799.	5.0	74

#	Article	IF	Citations
19	Comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. Journal of Nuclear Medicine, 2018, 59, 789-794.	5.0	68
20	¹¹¹In-Pentetreotide Scintigraphy Versus ⁶⁸Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. Journal of Nuclear Medicine, 2019, 60, 1266-1269.	5.0	66
21	FAP: The Next Billion Dollar Nuclear Theranostics Target?. Journal of Nuclear Medicine, 2020, 61, 163-165.	5.0	64
22	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. Journal of Nuclear Medicine, 2022, 63, 59-68.	5.0	61
23	Areas of High ¹⁸F-FDG Uptake on Preradiotherapy PET/CT Identify Preferential Sites of Local Relapse After Chemoradiotherapy for Nonâ€“Small Cell Lung Cancer. Journal of Nuclear Medicine, 2015, 56, 196-203.	5.0	59
24	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Research, 2018, 8, 96.	2.5	58
25	Delivering Radionuclide Therapies Requires Extensive Training and Competence: Send a Firm Message to the NRC and Your Representatives. Journal of Nuclear Medicine, 2019, 60, 1-2.	5.0	57
26	Diagnostic Impact of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and White Blood Cell SPECT/Computed Tomography in Patients With Suspected Cardiac Implantable Electronic Device Chronic Infection. Circulation: Cardiovascular Imaging, 2019, 12, e007188.	2.6	52
27	PSMA-targeted Radiotracers versus ¹⁸F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. Radiology, 2020, 296, 44-55.	7.3	49
28	The Future of Nuclear Medicine as an Independent Specialty. Journal of Nuclear Medicine, 2019, 60, 3S-12S.	5.0	47
29	Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. Journal of Urology, 2019, 202, 231-240.	0.4	46
30	Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET: Myth or Reality?. Journal of Nuclear Medicine, 2022, 63, 226-232.	5.0	42
31	The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 557-567.	5.0	41
32	Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. European Urology, 2020, 78, 148-154.	1.9	39
33	High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 858-867.	6.4	38
34	Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology, 2021, 299, 248-260.	7.3	38
35	Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4271-4281.	6.4	38
36	Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ¹⁷⁷Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. Journal of Nuclear Medicine, 2021, 62, 1440-1446.	5.0	37

#	Article	IF	Citations
37	Total-Body ⁶⁸Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines. Journal of Nuclear Medicine, 2020, 61, 405-411.	5.0	36
38	Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Pointâ€"An Important Diagnostic, Phenotypic, and Biomarker Role. American Journal of Roentgenology, 2021, 216, 305-306.	2.2	36
39	⁶⁸ Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. Journal of Urology, 2019, 202, 1174-1181.	0.4	33
40	Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. European Urology Focus, 2021, 7, 238-240.	3.1	31
41	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 501-508.	6.4	30
42	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. Journal of Nuclear Medicine, 2022, , jnumed.121.263072.	5.0	28
43	Salvage therapy for prostate cancer after radical prostatectomy. Nature Reviews Urology, 2021, 18, 643-668.	3.8	26
44	Non-oncologic incidental uptake on FAPI PET/CT imaging. British Journal of Radiology, 2023, 96, .	2.2	25
45	Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. Journal of Nuclear Medicine, 2017, 58, 1793-1796.	5.0	24
46	Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, jnumed.120.256263.	5.0	22
47	Detection Threshold and Reproducibility of ⁶⁸Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1392-1397.	5.0	21
48	Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review. European Urology Oncology, 2021, 4, 339-355.	5.4	20
49	A Comprehensive Assessment of ⁶⁸Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. Journal of Nuclear Medicine, 2022, 63, 567-572.	5.0	20
50	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. Journal of Nuclear Medicine, 2022, 63, 76-80.	5.0	20
51	Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. Journal of Nuclear Medicine, 2020, 61, 189-193.	5.0	19
52	Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. Journal of Nuclear Medicine, 2020, 61, 1037-1042.	5.0	19
53	68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 924-926.	6.4	19
54	Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. European Urology Oncology, 2022, 5, 100-103.	5.4	18

#	Article	IF	Citations
55	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomographyâ€"Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Network Open, 2021, 4, e2138550.	5.9	18
56	Radiation Dosimetry of ^{99m}Tc-PSMA I&S: A Single-Center Prospective Study. Journal of Nuclear Medicine, 2021, 62, 1075-1081.	5.0	17
57	Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma. Head and Neck, 2017, 39, 1155-1165.	2.0	16
58	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naÃ¯ve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. European Urology Oncology, 2022, 5, 544-552.	5.4	16
59	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296.	2.3	16
60	Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA. Journal of Nuclear Medicine, 2021, 62, 146-148.	5.0	15
61	Accuracy of ¹⁸F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study. Journal of Nuclear Medicine, 2021, 62, 1511-1516.	5.0	15
62	68Ga-FAPI-46 and 18F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3736-3737.	6.4	15
63	[¹⁷⁷Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial.. Journal of Clinical Oncology, 2022, 40, 5001-5001.	1.6	15
64	Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. BMC Cancer, 2021, 21, 512.	2.6	14
65	Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). Journal of Nuclear Medicine, 2021, 62, 1447-1456.	5.0	14
66	Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer. Clinical Nuclear Medicine, 2021, 46, e86-e87.	1.3	13
67	Hodgkinâ€™s Disease Staging by FDG PET/CT in a Pregnant Woman. Nuclear Medicine and Molecular Imaging, 2014, 48, 244-246.	1.0	12
68	Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen. Journal of Urology, 2022, 207, 769-778.	0.4	12
69	Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMAÂand Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 366-382.	3.8	12
70	Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis. EJNMMI Research, 2019, 9, 103.	2.5	11
71	RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5028-5028.	1.6	11
72	PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy. Journal of Nuclear Medicine, 2021, 62, 1489-1491.	5.0	11

#	Article	IF	Citations
73	The Impact of Monosodium Glutamate on ⁶⁸Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study. Journal of Nuclear Medicine, 2021, 62, 1244-1251.	5.0	10
74	Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. Radiotherapy and Oncology, 2022, 166, 1-7.	0.6	9
75	Resection of a Solitary Pulmonary Metastasis from Prostatic Adenocarcinoma Misdiagnosed as a Bronchocele: Usefulness of 18F-Choline and 18F-FDG PET/CT. Journal of Thoracic Oncology, 2014, 9, 1826-1829.	1.1	8
76	Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. Clinical Genitourinary Cancer, 2019, 17, e53-e55.	1.9	8
77	Non-invasive imaging techniques to assess myocardial perfusion. Expert Review of Medical Devices, 2020, 17, 1133-1144.	2.8	8
78	¹⁷⁷Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine. Journal of Nuclear Medicine, 2021, 62, 1025-1026.	5.0	8
79	[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. EJNMMI Research, 2020, 10, 122.	2.5	8
80	Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy.. Journal of Clinical Oncology, 2019, 37, 15-15.	1.6	8
81	Mycotic aneurysm in a pulmonary artery detected with 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. European Heart Journal, 2017, 38, ehw571.	2.2	7
82	Reply: Comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its Way. Journal of Nuclear Medicine, 2018, 59, 861-861.	5.0	7
83	Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial.. Journal of Clinical Oncology, 2018, 36, 5001-5001.	1.6	6
84	How Many Theranostics Centers Will We Need in the United States?. Journal of Nuclear Medicine, 2022, 63, 805-806.	5.0	6
85	18F-FDG PET/CT scan in malignant priapism with diffuse pulmonary adenocarcinoma metastatic invasion of both corpus spongiosum and cavernosum. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 588-589.	6.4	5
86	Prostate Cancer Pulmonary Metastasis Presenting as a Ground-Glass Pulmonary Nodule on 68Ga-PSMA-11 PET/CT. Clinical Nuclear Medicine, 2019, 44, e353-e356.	1.3	5
87	The Impact of 18F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 1364-1369.	1.2	5
88	PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. Lancet, The, 2021, 397, 768-769.	13.7	5
89	A Cardiac Myxoma With Intense Metabolic Activity. Canadian Journal of Cardiology, 2018, 34, 92.e11-92.e12.	1.7	4
90	What is the best PET target for early biochemical recurrence of prostate cancer?â€“Authorsâ€™ reply. Lancet Oncology, The, 2019, 20, e609-e610.	10.7	4

#	Article	IF	Citations
91	PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma. Clinical Nuclear Medicine, 2020, 45, e309-e310.	1.3	4
92	Overall survival after ¹⁷⁷Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial.. Journal of Clinical Oncology, 2020, 38, 5549-5549.	1.6	4
93	Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma. EJNMMI Research, 2022, 12, 4.	2.5	4
94	Reply to â€œ18F-Choline PET-CT in the Management of Lung Cancer and Mucinous Tumors?â€• Journal of Thoracic Oncology, 2015, 10, e49-e50.	1.1	3
95	Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration Method. Frontiers in Medicine, 2020, 7, 218.	2.6	3
96	Correlation between fluorodeoxyglucose hotspots on preradiotherapy PET/CT and areas of cancer local relapse: Systematic review of literature. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 444-452.	1.4	3
97	Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress. Clinical Cancer Research, 2021, 27, PO-077-PO-077.	7.0	3
98	18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Journal of Nuclear Medicine, 2022, 63, 199-204.	5.0	3
99	High 68ÂGa-FAPI-46 uptake in a pulmonary necrotizing granuloma in a patient with subcutaneous lipoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, , 1.	6.4	3
100	Randomized phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].. Journal of Clinical Oncology, 2019, 37, TPS136-TPS136.	1.6	3
101	More Unacceptable Denials: Now Itâ€™s PSMA-Targeted PET/CT Imaging. Journal of Nuclear Medicine, 2022, 63, 969-970.	5.0	3
102	Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. European Urology Open Science, 2020, 19, e1215-e1216.	0.4	2
103	Impact of 68 Ga-PSMA-11 PET on the Management of biochemically recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.7	2
104	Tc-99m-HMPAO-Labeled Leukocyte SPECT/CT in Pediatrics: Detecting Candida albicans Tricuspid Endocarditis. Nuclear Medicine and Molecular Imaging, 2015, 49, 333-334.	1.0	1
105	Randomized prospective phase 3 trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].. Journal of Clinical Oncology, 2019, 37, TPS5101-TPS5101.	1.6	1
106	Of Sheep and Wolves: Curtailing Coverage for Essential Imaging Tests Based on Flawed Use and Cost Arguments. Journal of Nuclear Medicine, 2019, 60, 1657-1658.	5.0	1
107	Douleurs jambiÃ¨res bilatÃ©rales sans orientation Ã©tiologique Ã©vidente. Feuillets De Radiologie, 2012, 52, 342-346.	0.0	0
108	68Ga-PSMA PET/CT Mapping of Prostate Cancer at Initial Staging: Potential Impact on Definitive Radiation Therapy Planning. International Journal of Radiation Oncology Biology Physics, 2018, 102, S162.	0.8	0

#	Article	IF	Citations
109	The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2253-2255.	6.4	0
110	We Can Make a Difference: Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate Cancer. European Urology Focus, 2021, 7, 227-228.	3.1	0
111	177Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine. Journal of Nuclear Medicine, 2021, 62, 1025-1026.	5.0	0
112	Perspectives on Cutting-Edge Clinical Trials. Journal of Nuclear Medicine, 2021, 62, 1027-1030.	5.0	0
113	Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study. SSRN Electronic Journal, 0, , .	0.4	0
114	Prospective head-to-head comparative phase 3 study between ¹⁸F-fluciclovine and ⁶⁸Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5014-5014.	1.6	0
115	Reply by Authors. Journal of Urology, 2019, 202, 1181-1181.	0.4	0
116	Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright. Journal of Nuclear Medicine Technology, 2020, 48, 82S-83S.	0.8	0
117	PSMA PET in Prostate Cancerâ€"A Biomarker or a Surrogate End Point?â€"Reply. JAMA Oncology, 2022, , .	7.1	0
118	Health Care and Nuclear Medicine in France. Journal of Nuclear Medicine, 2022, 63, 327-330.	5.0	0